Bristol Myers Squibb (CELG-RI) Current Assets (2009 - 2026)

Bristol Myers Squibb (CELG-RI) has reported Current Assets for 18 consecutive years, with $28.6 billion the latest figure, recorded in Q2 2026.

• On a quarterly basis, Current Assets fell 13.98% year-over-year to $28.6 billion in Q2 2026; TTM through Jun 2026 was $28.6 billion, a 13.98% decrease from a year earlier, with the FY2025 full-year figure at $29.4 billion, down 1.31% from the prior year.
• Current Assets was $28.6 billion for Q2 2026 at Bristol Myers Squibb, up from $27.2 billion in the prior quarter.
• Over five years, Current Assets peaked at $35.6 billion in Q3 2025 and troughed at $26.8 billion in Q3 2022.
• A 5-year average of $29.3 billion and a median of $28.6 billion in 2024 frame the typical range for Current Assets.
• Across the five-year window, Current Assets retreated 18.01% in 2022 and advanced 26.91% in 2025, its largest moves.
• Over 5 years, Current Assets stood at $27.3 billion in 2022, then increased by 16.49% to $31.8 billion in 2023, then slipped by 6.26% to $29.8 billion in 2024, then declined by 1.31% to $29.4 billion in 2025, then dropped by 2.76% to $28.6 billion in 2026.
• The last three Current Assets figures came in at $28.6 billion (Q2 2026), $27.2 billion (Q1 2026), and $29.4 billion (Q4 2025), per Business Quant data.